Comparative Pharmacology
Head-to-head clinical analysis: POMALYST versus REVLIMID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POMALYST versus REVLIMID.
POMALYST vs REVLIMID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pomalidomide is an immunomodulatory agent with antineoplastic activity. It inhibits proliferation and induces apoptosis of hematopoietic tumor cells. Additionally, it enhances T-cell- and natural killer (NK) cell-mediated immunity and inhibits angiogenesis by blocking the production of pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). The exact mechanism of its immunomodulatory and antineoplastic effects is not fully understood.
Revlimid (lenalidomide) is an immunomodulatory agent with antiangiogenic and antineoplastic properties. It inhibits tumor necrosis factor-alpha, stimulates T-cell proliferation and IL-2 production, and inhibits angiogenesis by blocking VEGF and bFGF. It also modulates the ubiquitin E3 ligase cereblon, leading to degradation of transcription factors Ikaros and Aiolos, which results in direct tumor cell apoptosis and enhanced immune function.
4 mg orally once daily on days 1-21 of repeated 28-day cycles in combination with dexamethasone, for multiple myeloma; for Kaposi sarcoma, 5 mg orally once daily on days 1-21 of 28-day cycles.
5-10 mg orally once daily for 21 days of a 28-day cycle; dose depends on indication (e.g., 10 mg for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes).
None Documented
None Documented
Terminal elimination half-life is approximately 7.5 hours in patients with multiple myeloma, allowing for once-daily dosing without accumulation at steady state.
Terminal elimination half-life of approximately 3-5 hours in patients with normal renal function. Half-life is prolonged in renal impairment (up to 9 hours in severe impairment).
Approximately 73% of radiolabeled pomalidomide is excreted in urine (primarily as metabolites, with <2% as unchanged drug) and 15% in feces. Renal clearance is the major elimination pathway.
Primarily renal excretion as unchanged drug (approximately 67% of the dose in urine over 24 hours) with minor fecal elimination (<4%).
Category C
Category C
Immunomodulatory Agent
Immunomodulatory Agent